On April 17, 2026 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, reported that it will be presenting a poster on its lead asset AT-108 at the AACR (Free AACR Whitepaper) Annual Meeting, held in San Diego, California, US, from 17-22 April 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AT-108 is a transformative gene therapy utilizing Asgard’s in vivo cell reprogramming technology to directly reprogram tumor cells into dendritic cells. This approach forces these tumor cells to present their tumor antigens, ultimately leading to a personalized anti-tumor immune response. Asgard is progressing its first-in-class therapy toward clinical development, with a focus on solid tumors, and is advancing IND-enabling studies and CMC development.
The poster presentation, titled ‘Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent’, will detail preclinical data demonstrating that AT-108 induces systemic, dose-dependent efficacy with broad tumor activity. Key biomarker parameters were highlighted to be explored in future clinical development.
Details of the poster presentation are as follow:
Poster title: Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent
Presenter: Fabio Rosa, Asgard Therapeutics
Authors: Fritiof Åkerström1, Xavier Catena1, Marta Santiago2, Ana Perego1, Ruixian Liu1, Arun Sundaramurthy1, Lihan Xie1, Emilie Renaud1, Andreea-Medeea Matei1, Xiaoli Huang1, Emma Leire1, Ozcan Met2, Inge-Marie Svane2, Shane Olwill1, Cristiana Pires1, Filipe Pereira3, Fabio Rosa1
Poster session: Session LBPO.ET04 – Late-Breaking Research: Experimental and Molecular Therapeutics 4
Session date and time: 22 April, 2026, 9:00 AM – 12:00 PM PDT
Location: Section 53
Poster number: LB455 / 2
1Asgard Therapeutics AB, Lund, Sweden,2National Center of Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark,3Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, Lund, Sweden
The abstract is available to view via the AACR (Free AACR Whitepaper) online planner.
(Press release, Asgard Therapeutics, APR 17, 2026, View Source [SID1234664467])